Could polyols (non-absorbed sugars/sugar alcohols) in the placebo in #IBS studies affect the outcome of the trial? Maybe... Check out our Cedars-Sinai Academic Medicine MAST Research Program study with Ali Rezaie MD MSc and our resident Dr. Jonathan Busam. cghjournal.org/article/S1542-…

Right now Anthony Lembo, MD telling us about #gastroparesis and emerging therapies. These patients desperately need meds that work. Future is still unclear. #GIReconnect

Great talk now on capsule technologies for the diagnosing gut disorders by Baha Moshiree MD, MSci, FACG, AGAF. She is a leading expert and the age of ingestable smart capsules is upon us.

Breath Testing indications as presented from global guidelines presented here by #SatishRaoMD Gi Health Foundation today Amit Patel, MD, AGAF, FACG Mark Pimentel MD Ali Rezaie MD MSc Rajan Singh 🤗👏Helpful to see that not all globally agree but a nice start

Wednesday Question...Which of the following has large scale prospective study cause-and-effect evidence for #IBS-D?

Great for the 69%! The rest of you, keep reading...there are large prospective studies proving the development of #IBS after food poisoning. A recent study showed that Camplybacter jejuni meets the stringent Bradford Hill cause-and-effect criteria for development of #IBS.

Our study confirms that both direct and indirect effects of narrow-band UVA light on #SARSCoV2 are not dependent on variant. UVA activates cells into an antiviral state. sciencedirect.com/science/articl… #COVID19

Well, that's a first! Our paper's imaginative illustration of "carrot trachea with steak lungs on a plate" made it to the cover of the Gastroenterology journal!

Could what you put in placebo during #IBS trials affect the outcome of a trial? Maybe. Non-absorbed sugars are often fillers but are known to cause symptoms in #IBS. See this study that just published in CGH by Dr. Jonathan Busam, Ali Rezaie MD MSc and I. sciencedirect.com/science/articl…

Our paper on the role of elemental diet in treatment of various GI disorders #CD #UC #SIBO #IMO #IBD #celiac #EOE #EGID #Pancreatitis Precision dietary interventions can have profound effects on health and disease link.springer.com/article/10.100…

We are finally preparing for a new drug trial for #IBS-D based on the microbiome. Hoping this will be running in October! Stay tuned.

Linda Ánh Vân Nguyễn MD presents ANMS on gender gap in #Medicine Recipient of the #Woman 👸🏽in Neuro GI today! Anita Afzali MD, MPH, MHCM, FACG, AGAF Amy Oxentenko MD Mariam Naveed, MD Aline Charabaty, MD, FACG, AGAF Neena S Abraham MD MACG FASGE AGAF Katie Hutchins, MD AJG - The American Journal of Gastroenterology data on gender pay gaps presented Patrick Young John E. Pandolfino Mark Pimentel MD

Congratulations to Linda Ánh Vân Nguyễn MD from Stanford Div. of GI & Hepatology for being awarded the distinguished investigator award ANMS meeting. A good friend and a great leader!

Another ICYMI #DDW2024 edition❗️ Our abstract found that severity of self-reported bloating correlates w/ excessive growth of coliforms, meeting the definition of #SIBO in the duodenum Digestive Disease Week Cedars-Sinai Academic Medicine

If we continue to base #IBS diagnosis on symptoms, we will continue to get drugs that just treat symptoms (and have no grants to fund research). Time to base diagnosis and treatment on pathophysiology in the gut.

Just published! This paper is a game changer for patients. 1. CdtB causes #IBS 2. Animal model shows #IBS is #SIBO 3. Rifaximin+NAC beats rifaximin in randomized trial. 4. E. Coli and H2S producers are key. Lays groundwork for our human study this fall. nature.com/articles/s4159…

Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial Mark Pimentel MD nature.com/articles/s4159…

Our study summarizing GI symptoms associated with intestinal methanogen overgrowth (IMO) sciencedirect.com/science/articl…

Nice study from Dr. Irene Sonu, Sean Spencer, MD, PhD and others from Stanford. This shows using wireless capsule that intestinal methanogen overgrowth (#IMO) is associated with delayed small bowel and colonic transit (AKA #constipation). link.springer.com/article/10.100…

A special day with patient 1000 in the REIMAGINE study. A massive effort to study the small intestinal #microbiome and new associations between single bacteria and human disease. Thanks to those who support this research! You will see great things in the coming months.